Alfasigma
Bologna, Emilia Romagna, Italy · Biotechnology, Health Care, Manufacturing
Alfasigma is one of Italy's leading pharmaceutical companies with a strong international position. The Group has a worldwide presence in over 100 countries where about 3000 people work in research, development, production and distribution. In Italy, Alfasigma is a leader in the prescription products market where, in addition to its strong focus on gastro-intestinal products, it is present in sever
Key facts
- Headquarters
- Bologna, Emilia Romagna, Italy
- Employees
- 3,500
- Industries
- Biotechnology, Health Care, Manufacturing
- Website
- alfasigma.com
- Company page
Recent activity at Alfasigma
- : Alfasigma acquires Nordic Pharma for global expansion
- : Alfasigma to acquire Nordic Group B.V.
- : Alfasigma Partners with Innovative Molecules to License Adibelivir for Treating HSV Encephalitis.
- : Alfasigma Completes Acquisition Of Intercept Pharmaceuticals, Inc.
- : Alfasigma To Acquire Intercept Pharmaceuticals For $19.00 Per Share In Cash, Expanding The Global Footprint Of Alfasigma Via A Leader In Rare And Serious Liver Diseases
- : Alfasigma Acquires The Entire Share Capital Of Sofar, An Italian Pharmaceutical Company
Leadership
- Flaminia, Senior Talent Acquisition Partner
- Federica, Senior Global Talent Acquisition Partner
Verified email and direct lines for Alfasigma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Alfasigma files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Alfasigma in the news
- Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe - Business Wire (Aug 11, 2026)
- Alfasigma gains arthritis drug, access to new markets with M&A play - Fierce Pharma (Aug 12, 2026)
- Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision - Fierce Biotech (Mar 09, 2026)
- GSK sells liver disease drug candidate to Alfasigma for $690m - Pharmaceutical Technology (Mar 09, 2026)
- Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease - PR Newswire (Jan 14, 2026)
- GSK licenses pill for liver disease itch to Alfasigma for $300M upfront - Endpoints News (Mar 09, 2026)
- After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy's Alfasigma - Fierce Pharma (Sep 26, 2023)
- ALFASIGMA ANNOUNCES THE AGREEMENT FOR THE ACQUISITION OF 100% OF SOFAR, ITALIAN PHARMACEUTICAL COMPANY - PR Newswire UK (Aug 02, 2022)
Companies similar to Alfasigma
- Aarti Pharmalabs · Biotechnology, Health Care, Manufacturing
- Otsuka America Pharmaceutical · Biotechnology, Health Care, Manufacturing
- Masimo Corporation · Biotechnology, Health Care, Manufacturing
- Jazz Pharmaceuticals plc · Biotechnology, Health Care, Manufacturing
- Zentiva AG · Biotechnology, Health Care, Manufacturing
About Alfasigma: questions and answers
What does Alfasigma do?
Alfasigma is one of Italy's leading pharmaceutical companies with a strong international position. The Group has a worldwide presence in over 100 countries where about 3000 people work in research, development, production and distribution. In Italy, Alfasigma is a leader in the prescription products market where, in addition to its strong focus on gastro-intestinal products, it is present in sever
Where is Alfasigma headquartered?
Alfasigma is headquartered in Bologna, Emilia Romagna, Italy.
How many employees does Alfasigma have?
Alfasigma has about 3,500 employees.
What is the latest news on Alfasigma?
On Aug 15, 2026, Alfasigma acquires Nordic Pharma for global expansion
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy